APREA THERAPEUTICS, INC.

(APRE)
  Report
Delayed Nasdaq  -  04:00 2022-08-12 pm EDT
0.9500 USD   -3.90%
08/12APREA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
08/11APREA THERAPEUTICS : Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations - Form 8-K
PU
08/11Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Aprea Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

05/16/2022 | 09:21am EDT

Aprea Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 7.94 million compared to USD 9.67 million a year ago. Basic loss per share from continuing operations was USD 0.36 compared to USD 0.46 a year ago. Diluted loss per share from continuing operations was USD 0.36 compared to USD 0.46 a year ago.


© S&P Capital IQ 2022
All news about APREA THERAPEUTICS, INC.
08/12APREA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
08/11APREA THERAPEUTICS : Reports Second Quarter 2022 Financial Results and Provides Update on ..
PU
08/11Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on..
GL
08/02APREA THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
08/02Aprea Therapeutics, Inc. Elects John B. Henneman III and Christian S. Schade as Directo..
CI
08/02Aprea Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Conference
GL
08/02Aprea Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Conference
AQ
07/29APREA THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing R..
AQ
07/08Top Premarket Gainers
MT
07/07Wedbush Initiates Aprea Therapeutics With Outperform Rating, $3 Price Target
MT
More news
Analyst Recommendations on APREA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -33,7 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,61x
Yield 2022 -
Capitalization 22,2 M 22,2 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees -
Free-Float 89,2%
Chart APREA THERAPEUTICS, INC.
Duration : Period :
Aprea Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends APREA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 0,95 $
Average target price 3,00 $
Spread / Average Target 216%
EPS Revisions
Managers and Directors
Oren Gilad President, Chief Executive Officer & Director
Scott M. Coiante Chief Financial Officer, Secretary & Senior VP
Christian S. Schade Chairman
Eyal C. Attar Chief Medical Officer & Senior Vice President
Lars Abrahmsén Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
APREA THERAPEUTICS, INC.-66.90%22
MODERNA, INC.-32.60%66 966
IQVIA HOLDINGS INC.-12.88%45 846
LONZA GROUP AG-25.13%44 851
SEAGEN INC.10.05%31 380
ALNYLAM PHARMACEUTICALS, INC.37.90%28 068